BR112017014924A2 - Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias - Google Patents
Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatóriasInfo
- Publication number
- BR112017014924A2 BR112017014924A2 BR112017014924A BR112017014924A BR112017014924A2 BR 112017014924 A2 BR112017014924 A2 BR 112017014924A2 BR 112017014924 A BR112017014924 A BR 112017014924A BR 112017014924 A BR112017014924 A BR 112017014924A BR 112017014924 A2 BR112017014924 A2 BR 112017014924A2
- Authority
- BR
- Brazil
- Prior art keywords
- surgery
- patient
- supplement
- induced
- day
- Prior art date
Links
- 238000001356 surgical procedure Methods 0.000 title abstract 6
- 206010006895 Cachexia Diseases 0.000 title abstract 2
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 230000000770 proinflammatory effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000013589 supplement Substances 0.000 abstract 4
- 210000004479 myeloid suppressor cell Anatomy 0.000 abstract 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010021333 Ileus paralytic Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 208000035965 Postoperative Complications Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940124280 l-arginine Drugs 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 1
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 1
- 239000006014 omega-3 oil Substances 0.000 abstract 1
- 201000007620 paralytic ileus Diseases 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 235000019155 vitamin A Nutrition 0.000 abstract 1
- 239000011719 vitamin A Substances 0.000 abstract 1
- 229940045997 vitamin a Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
um suplemento imunonutricional especializado pode ser administrado a um paciente cirúrgico para reduzir as complicações pós-operatórias pela restrição da expansão de células supressoras de origem mieloide. o suplemento inclui um ou mais entre l-arginina, ácidos graxos ômega-3, vitamina a e nucleotídeos dietários, de preferência, todos estes quatro compostos. o suplemento é administrado ao paciente ao menos uma vez ao dia por um período que se estende desde um dia antes da cirurgia, ou seja, de três a sete dias antes de uma cirurgia de bexiga do paciente, até um dia após a cirurgia, ou seja, de três a sete dias após a cirurgia de bexiga. o suplemento pode ser administrado para tratar ou prevenir íleo paralítico pós-operatório em um paciente com câncer de bexiga; tratar ou prevenir a caquexia induzida por cirurgia, induzida por inflamação ou induzida por câncer; reduzir a incidência de infecções crônicas resultantes da expansão de células supressoras de origem mieloide em um paciente; e/ou reduzir a expressão de mrna de citoquinas pró-inflamatórias em um paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562116155P | 2015-02-13 | 2015-02-13 | |
PCT/EP2016/053156 WO2016128576A1 (en) | 2015-02-13 | 2016-02-15 | Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017014924A2 true BR112017014924A2 (pt) | 2018-03-20 |
Family
ID=55353231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017014924A BR112017014924A2 (pt) | 2015-02-13 | 2016-02-15 | Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias |
Country Status (8)
Country | Link |
---|---|
US (2) | US11857525B2 (pt) |
EP (1) | EP3256111A1 (pt) |
JP (2) | JP2018510129A (pt) |
CN (1) | CN107205962B (pt) |
AU (3) | AU2016217818A1 (pt) |
BR (1) | BR112017014924A2 (pt) |
CA (1) | CA2974870C (pt) |
WO (1) | WO2016128576A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
EA201891926A1 (ru) * | 2017-02-03 | 2019-04-30 | Киверди, Инк. | Микроорганизмы и искусственные экосистемы для производства белка, продуктов питания и полезных побочных продуктов из субстратов c1 |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
CA3128973A1 (en) | 2019-03-04 | 2020-09-10 | Bhaskar Bhattacharyya | Data compression and communication using machine learning |
CA3188591A1 (en) * | 2020-07-10 | 2022-01-13 | Duke University | Compositions and methods for treating cancer-associated cachexia |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3901048A1 (de) | 1989-01-14 | 1990-07-19 | Chimicasa Gmbh | Antikachectikum |
EP0960572A1 (en) * | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
CN1810238A (zh) * | 2005-01-24 | 2006-08-02 | 姜广良 | 精氨酸口服配方预防和治疗恶液质综合症 |
CN102164595A (zh) * | 2008-09-19 | 2011-08-24 | 雀巢产品技术援助有限公司 | 抗癌治疗中的免疫***营养支持 |
JP2014510530A (ja) | 2011-03-31 | 2014-05-01 | ネステク ソシエテ アノニム | アルギニンレベルを増加させる栄養組成物及びその使用方法 |
-
2016
- 2016-02-15 JP JP2017538707A patent/JP2018510129A/ja active Pending
- 2016-02-15 CA CA2974870A patent/CA2974870C/en active Active
- 2016-02-15 AU AU2016217818A patent/AU2016217818A1/en not_active Abandoned
- 2016-02-15 WO PCT/EP2016/053156 patent/WO2016128576A1/en active Application Filing
- 2016-02-15 CN CN201680008209.XA patent/CN107205962B/zh active Active
- 2016-02-15 BR BR112017014924A patent/BR112017014924A2/pt not_active Application Discontinuation
- 2016-02-15 US US15/548,186 patent/US11857525B2/en active Active
- 2016-02-15 EP EP16704256.3A patent/EP3256111A1/en active Pending
-
2020
- 2020-11-02 JP JP2020183624A patent/JP7237050B2/ja active Active
-
2021
- 2021-03-19 AU AU2021201741A patent/AU2021201741B2/en active Active
-
2023
- 2023-07-20 AU AU2023206185A patent/AU2023206185A1/en active Pending
- 2023-11-07 US US18/387,738 patent/US20240065996A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2974870A1 (en) | 2016-08-18 |
AU2023206185A1 (en) | 2023-08-10 |
AU2021201741B2 (en) | 2023-04-27 |
US11857525B2 (en) | 2024-01-02 |
JP2021045129A (ja) | 2021-03-25 |
US20180021279A1 (en) | 2018-01-25 |
CN107205962B (zh) | 2020-10-02 |
JP2018510129A (ja) | 2018-04-12 |
US20240065996A1 (en) | 2024-02-29 |
EP3256111A1 (en) | 2017-12-20 |
AU2021201741A1 (en) | 2021-04-15 |
WO2016128576A1 (en) | 2016-08-18 |
AU2016217818A1 (en) | 2017-07-13 |
CN107205962A (zh) | 2017-09-26 |
CA2974870C (en) | 2024-04-16 |
JP7237050B2 (ja) | 2023-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017014924A2 (pt) | Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias | |
BR112019005930A2 (pt) | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas | |
MX2020012595A (es) | Composiciones farmaceuticas topicas. | |
BR112014016788A2 (pt) | composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
BR112017027836A2 (pt) | método para o tratamento de inflamação usando compostos naturais e/ou dieta | |
BR112015000136A2 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
Tripathi et al. | Mitophagy in depression: pathophysiology and treatment targets | |
BR112016000335A8 (pt) | método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica | |
BR112013000190A2 (pt) | formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide | |
BR112018000242A2 (pt) | composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico | |
BR112018008186A2 (pt) | métodos que utilizam proteína de soro de leite para melhorar ou manter a qualidade muscular | |
BR112016021985A8 (pt) | formulação farmacêutica e composto | |
BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
BR112022016360A2 (pt) | Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos | |
WO2015035410A8 (en) | Cancer therapy | |
BR112015009504A2 (pt) | inibidores de rock | |
BR112021010865A2 (pt) | Composição compreendendo um pepitídeo inibidor contra a sinalização de fas e uso dos mesmo para prevenção ou tratamento da obesidade, fígado gorduroso ou esteato-hepatite | |
BR112017019480A2 (pt) | dosagem unitária de composição vitamínica ampliável, e, método para tratar uma deficiência de vitamina lipossolúvel. | |
BR112014033088A2 (pt) | composição para prevenção ou tratamento de colite compreendendo s-alil-l-cisteína como ingrediente ativo, e preparação médica compreendendo a mesma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |